1
|
Baqui AH, Koffi AK, McCollum ED, Roy AD, Chowdhury NH, Rafiqullah I, Ahmed ZB, Mahmud A, Begum N, Ahmed S, Khanam R, Harrison M, Simmons N, Hossen S, Islam M, Quaiyum A, Checkley W, Santosham M, Moulton LH, Saha SK. Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies. Vaccine 2021; 39:5794-5801. [PMID: 34465471 DOI: 10.1016/j.vaccine.2021.08.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 08/14/2021] [Accepted: 08/18/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Bangladesh introduced the ten-valent pneumococcal conjugate vaccine (PCV10) into its national immunization program in March 2015 creating an opportunity to assess the real-world impact of PCV on invasive pneumococcal disease (IPD). METHODS Between January 2014 and June 2018, children aged 3-35 months in three rural sub-districts of Sylhet district of Bangladesh were visited every two months to collect morbidity and care-seeking data. Children attending sub-district hospitals with pneumonia, meningitis, or sepsis were assessed for IPD after obtaining informed consent. Blood and cerebrospinal fluid were collected from enrolled children to isolate pneumococcus using culture and molecular test. Children who were age-eligible to receive the PCV and had pneumococcus isolated were enrolled as cases. Four age and sex-matched clinic and community controls were selected for each case within one to two weeks of case identification. Data on immunization status and confounders were collected. PCV coverage was estimated using vaccine coverage surveys. Case-control and incidence trend analyses were conducted to assess the impact of PCV on IPD. RESULTS The community cohort yielded 217,605 child years of observations and 154,773 sick child-visits to study hospitals. Pneumococcus was isolated from 44 children who were age-eligible to receive PCV; these children were enrolled as cases. The cases were matched with 166 community- and 150 clinic-controls. The matched case-control analyses using community-controls showed 83% effectiveness (95% CI: 1.57-97.1%) and clinic controls showed 90% effectiveness (95% CI: -26.0% to 99.1%) of PCV in preventing IPD. Incidence trend analysis estimated vaccine effectiveness at 80.1% (95% CI: 38.4, 93.6). CONCLUSION PCV in this pediatric population in Bangladesh was highly effective in preventing IPD.
Collapse
Affiliation(s)
- Abdullah H Baqui
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
| | - Alain K Koffi
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Eric D McCollum
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Global Program in Respiratory Sciences, Department of Pediatrics, Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | | | | | - Iftekhar Rafiqullah
- Department of Microbiology and Immunology, University of Mississippi Medical Center (UMMC), Jackson, MS, United States
| | | | - Arif Mahmud
- Projahnmo Research Foundation, Dhaka, Bangladesh
| | - Nazma Begum
- Projahnmo Research Foundation, Dhaka, Bangladesh
| | | | - Rasheda Khanam
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Meagan Harrison
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Nicole Simmons
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Shakir Hossen
- Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | | | - Abdul Quaiyum
- International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
| | - William Checkley
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Center for Global Non-Communicable Disease Research and Training, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Mathuram Santosham
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Lawrence H Moulton
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Samir K Saha
- Child Health Research Foundation, Dhaka, Bangladesh
| | | |
Collapse
|
2
|
Saha S, Malaker R, Sajib MSI, Hasanuzzaman M, Rahman H, Ahmed ZB, Islam MS, Islam M, Hooda Y, Ahyong V, Vanaerschot M, Batson J, Hao S, Kamm J, Kistler A, Tato CM, DeRisi JL, Saha SK. Complete Genome Sequence of a Novel Coronavirus (SARS-CoV-2) Isolate from Bangladesh. Microbiol Resour Announc 2020; 9:e00568-20. [PMID: 32527780 PMCID: PMC7291105 DOI: 10.1128/mra.00568-20] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Accepted: 05/24/2020] [Indexed: 11/20/2022] Open
Abstract
The complete genome sequence of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) isolate obtained from a nasopharyngeal swab from a patient with COVID-19 in Bangladesh is reported.
Collapse
Affiliation(s)
- Senjuti Saha
- Child Health Research Foundation, Dhaka, Bangladesh
| | - Roly Malaker
- Child Health Research Foundation, Dhaka, Bangladesh
| | | | | | | | | | | | | | - Yogesh Hooda
- Child Health Research Foundation, Dhaka, Bangladesh
- MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
| | - Vida Ahyong
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | | | - Joshua Batson
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | - Samantha Hao
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | - Jack Kamm
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | - Amy Kistler
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | | | - Joseph L DeRisi
- Chan Zuckerberg Biohub, San Francisco, California, USA
- Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA
| | - Samir K Saha
- Child Health Research Foundation, Dhaka, Bangladesh
- Department of Microbiology, Dhaka Shishu Hospital, Bangladesh Institute of Child Health, Dhaka, Bangladesh
| |
Collapse
|
3
|
Kmush BL, Labrique AB, Dalton HR, Ahmed ZB, Ticehurst JR, Heaney CD, Nelson KE, Zaman K. Two Generations of "Gold Standards": The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence. Am J Trop Med Hyg 2015; 93:714-717. [PMID: 26149865 PMCID: PMC4596587 DOI: 10.4269/ajtmh.15-0159] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 05/12/2015] [Indexed: 12/13/2022] Open
Abstract
Hepatitis E virus (HEV) is a global pathogen responsible for approximately 20 million infections every year in developing countries, yet remains under-recognized. In this population-based cohort study, 1,025 randomly selected participants were enrolled from Matlab, Bangladesh (2004-2005). All participants were tested for HEV antibodies and total immunoglobulin (Ig), using an in-house enzyme immunoassay developed by Walter Reed Army Institute of Research (WRAIR). In 2014, we retested the banked sera of 1,009 of those participants using the Wantai anti-HEV IgG enzyme-linked immunosorbent assay (ELISA). The WRAIR assay estimated the overall population seroprevalence as 26.6% (95% confidence interval [CI]: 24.0, 29.5), whereas the Wantai assay produced significantly higher estimated seroprevalence, 46.7% (95% CI: 43.5-49.8) (P < 0.001). However, the two tests give nearly identical findings in those 5 years and under (N = 94) with a 98% agreement between the tests. Retesting populations with modern assays is necessary to establish better population-level estimates of disease burden.
Collapse
Affiliation(s)
| | - Alain B. Labrique
- *Address correspondence to Alain B. Labrique, Department of International Health, Johns Hopkins Bloomberg School of Public Health, W5501, 615 North Wolfe Street, Baltimore, MD 21205. E-mail:
| | | | | | | | | | | | | |
Collapse
|
4
|
Izopet J, Labrique AB, Basnyat B, Dalton HR, Kmush B, Heaney CD, Nelson KE, Ahmed ZB, Zaman K, Mansuy JM, Bendall R, Sauné K, Kamar N, Arjyal A, Karkey A, Dongol S, Prajapati KG, Adhikary D. Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. J Clin Virol 2015; 70:39-42. [PMID: 26305817 DOI: 10.1016/j.jcv.2015.06.103] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 06/24/2015] [Accepted: 06/27/2015] [Indexed: 12/15/2022]
Abstract
BACKGROUND Hepatitis E causes a significant burden of disease in developing countries and has recently been increasingly recognized in developed countries. Comparing population anti-hepatitis E virus (HEV) seroprevalence across populations has been difficult. OBJECTIVES The aim of this study was to compare the anti-HEV IgG seroprevalence in both adults and children in three hyper-endemic areas (Nepal, Bangladesh and southwest France) using a sensitive, commercial anti-HEV IgG assay. STUDY DESIGN Serum or plasma from adults and children in Nepal (n=498), Bangladesh (n=1,009) and Southwest France (n=1031) were tested for anti-HEV IgG using the Wantai assay. RESULTS After age-standardization, anti-HEV IgG seroprevalence was 47.1%, 49.8% and 34.0% in Nepal, Bangladesh and southwest France, respectively. There was no difference in seroprevalence by gender in any of the countries. A paucity of infections in children 1-10 years-old was consistently observed (less than 15%) at all 3 locations. CONCLUSIONS Surprisingly similar high rates of anti-HEV antibodies were detected using a common, sensitive assay. Despite differences in the epidemiology and circulating genotype of HEV in Nepal, Bangladesh and southwest France, this study found more similarities in population seroprevalence than expected.
Collapse
Affiliation(s)
- Jacques Izopet
- Université Toulouse III Paul Sabatier, Toulouse, France; Inserm, U1043, Toulouse, France; Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Alain B Labrique
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Buddha Basnyat
- Oxford University Clinical Research Unit\Patan Hospital, Kathmandu, Nepal
| | - Harry R Dalton
- University of Exeter, Truro, Cornwall, UK; Royal Cornwall Hospital Trust, Truro, Cornwall, UK
| | - Brittany Kmush
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | | | - Kenrad E Nelson
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Zabed B Ahmed
- Child Health Research Foundation, Department of Microbiology, Dhaka Shishu Hospital, Dhaka, Bangladesh
| | | | | | - Richard Bendall
- University of Exeter, Truro, Cornwall, UK; Royal Cornwall Hospital Trust, Truro, Cornwall, UK
| | - Karine Sauné
- Université Toulouse III Paul Sabatier, Toulouse, France; Inserm, U1043, Toulouse, France; Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Nassim Kamar
- Université Toulouse III Paul Sabatier, Toulouse, France; Inserm, U1043, Toulouse, France; Hôpital Rangueil, CHU de Toulouse, Toulouse, France
| | - Amit Arjyal
- Oxford University Clinical Research Unit\Patan Hospital, Kathmandu, Nepal
| | - Abhilasha Karkey
- Oxford University Clinical Research Unit\Patan Hospital, Kathmandu, Nepal
| | - Sabina Dongol
- Oxford University Clinical Research Unit\Patan Hospital, Kathmandu, Nepal
| | | | - Dinesh Adhikary
- Oxford University Clinical Research Unit\Patan Hospital, Kathmandu, Nepal
| |
Collapse
|